Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)

• Status: Completed
• Trial end date: 2020-06-14
• Target enrollment: 0
• Participant gender: All

Summary

The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract. Around 20% of those infected have severe pneumonia and currently there is no specific or effective therapy to treat this disease. Therapeutic options using malaria drugs chloroquine and hydroxychloroquine have shown promising results in vitro and in vivo test. But those efforts have not involved large, carefully-conducted controlled studies that would provide the global medical community the proof that these drugs work on a significant scale. In this way, the present study will evaluate the effectiveness and safety of the use of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with pneumonia by SARS-CoV2 virus.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Israelita Albert Einstein
• Collaborators: Brazilian Research In Intensive Care Network; EMS; Hospital do Coracao; Hospital Sirio-Libanes
• Treatments: Azithromycin; Hydroxychloroquine

Criteria

Inclusion Criteria:

1. Males and females aged > 18 years;

2. Suspected or confirmed infection by SARS-CoV2;

Presenting with one of the following:

• Need for oxygen supplementation > 4 L/min, or

• Need for high-flow nasal canula, or

• Need for non-invasive ventilation, or

• Need for mechanical ventilation.

Exclusion Criteria:

1. Refusal to provide written informed consent (either the patient or a legal representative);

2. Hypersensitivity to any of the drugs used in the study (Azithromycin or Hydroxychloroquine);

3. Patients with more than 48 hours of prior study medication use;

4. Patients with onset of symptoms longer than 14 days;

5. Patients with long QT syndrome or severe ventricular arrhythmias, not protected by an implantable cardioverter defibrillators (ICD).;

6. QTc>= 480ms;

7. Do not resuscitate order or exclusive palliative care;

8. Patients with liver disease or cirrhosis or abnormal liver enzyme tests above three times the upper limit values (alanine aminotransferase -ALT and aspartate aminotransferase - AST);

9. Patients with known retinopathy or macular degeneration;

10. Patients with history of pancreatitis;

11. Patients with concomitant use of medications that alter the absorption or excretion of azithromycin or hydroxychloroquine;

12. Breastfeeding women;

13. Pregnancy